Sirona
Phase 1- Indications
- Obesity, Type 2 diabetes, Non-alcoholic steatohepatitis
Company intelligence / Profile preview
Oxford Medical Products has developed "Sirona," a non-invasive oral hydrogel pill that swells in the stomach to suppress appetite mechanically. In its second UK-based clinical trial, Sirona demonstrated promising weight loss results across obese and overweight populations. The company plans to start pivotal trials in Q2 of 2025. Early preclinical data also support the use of their hydrogel as a gastroretentive platform for improved oral bioavailability of small molecules and peptides.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Oxford Medical Products.